Hybridoma technology: a brief review on its diagnostic and clinical significance

Subha Ganguly, Rajesh Wakchaure

Abstract


The term hybridoma was coined by Leonard Herzenberg in the laboratory of César Milstein's in 1976–1977. Hybridoma technology is the method in which large quantity of identical antibodies are produced which are also known as monoclonal antibodies. It is done by the administration of antigen in mouse which produces an immune response. The B-cells producing antibodies are then harvested from the injected mouse. The harvested B-cells are then fused with B cancer cells which remain immortal. This produces hybrid cell line called hybridoma which possesses the antibody-producing ability of the B-cell. The hybridomas can be grown in culture with one viable cell which produces cultures having genetically identical hybridomas. It produces monoclonal antibodies. It retains the ability to grow in tissue culture and do not possess antibody producing capability.


Keywords


B-cells, Hybridoma, Monoclonal antibodies

Full Text:

PDF HTML XML

References


Milstein C. The hybridoma revolution: an offshoot of basic research. BioEssays. 1999;21(11):966–73.

Nelson PN, Reynolds GM, Waldron EE, Ward E, Giannopoulos K, Murray PG. Demystified: Monoclonal antibodies. Molecular pathology. 2000;53(3):111–7.

Bretton PR, Melamed MR, Fair WR, Cote RJ. Detection of occult micrometastases in the bone marrow of patients with prostate carcinoma. Prostate. 1994;25(2):108–14.

Kvalheim G. Detection of occult tumor cells in bone marrow and blood in breast cancer patients—methods and clinical significance. Acta Oncol. 1996a;35:13–8.

Kvalheim G. Diagnosis of minimal residual disease in bone marrow and blood in cancer patients--methods and clinical implications. Acta oncologica (Stockholm, Sweden). 1998b;37(5):455–62.

Franklin WA, Shpall EJ, Archer P, Johnston CS, Garza-Williams S, Hami L, et al. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. Breast Cancer Res Treat. 1996;41(1):1–13.

Ghosh AK, Mason DY, Spriggs AI. Immunocytochemical staining with monoclonal antibodies in cytologically "negative" serous effusions from patients with malignant disease. J Clin Pathol. 1983a;36(10):1150–3.

Ghosh AK, Spriggs AI, Taylor-Papadimitriou J, Mason DY. Immunocytochemical staining of cells in pleural and peritoneal effusions with a panel of monoclonal antibodies. J Clin Pathol. 1983b;36(10):1154–64.


Refbacks

  • There are currently no refbacks.




Copyright (c) 2016 Pharmaceutical and Biological Evaluations

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.



Creative Commons License

 

© Copyright 2018 - Pharmaceutical and Biological Evaluations